



## **Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018**

September 25, 2018

— Presentation to be webcast on [www.exelixis.com](http://www.exelixis.com) —

ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 25, 2018-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide an overview of the company at the Cantor Fitzgerald Global Healthcare Conference taking place October 1-3 in New York, NY. The Exelixis presentation is scheduled for 9:10 AM EDT / 6:10 AM PDT on Tuesday, October 2, 2018.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

### **About Exelixis**

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our three commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. In July 2018, Exelixis was added to the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit <http://www.exelixis.com>, follow @ExelixisInc on Twitter or like ExelixisInc on Facebook.

*Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.*

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180925006115/en/>

Source: Exelixis, Inc.

### **Investors Contact:**

*Exelixis, Inc.*

*Susan Hubbard, 650-837-8194*

*EVP, Public Affairs and Investor Relations*

[shubbard@exelixis.com](mailto:shubbard@exelixis.com)

or

### **Media Contact:**

*For Exelixis, Inc.*

*Hal Mackins, 415-994-0040*

[hal@torchcommunications.com](mailto:hal@torchcommunications.com)